Expertise in

conditions

Alexandre Belot

Groupement Hospitalier Est,

Lyon, FR

Clinical Trials:Currently Recruiting for 1 Trial

Expertise in

conditions

Groupement Hospitalier Est,

Lyon, FR

Overview

Alexandre Belot practices practicing medicine in Lyon, France.

Mr. Belot is highly rated in 35 conditions, according to our data. His clinical expertise encompasses Multisystem Inflammatory Syndrome in Children (MIS-C), Juvenile Idiopathic Arthritis (JIA), Systemic Lupus Erythematosus (SLE), and Aicardi-Goutieres Syndrome.

He is actively involved in clinical research, co-authoring 290 peer reviewed articles and participating in 11 clinical trials.

Gender

Male

Locations

Groupement Hospitalier Est, Lyon, France

Other Locations

hôpitaux Est
Lyon, 69000, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA)

Enrollment Status: Recruiting

Publish Date: August 24, 2026

Intervention Type: Drug

Study Drug: Baricitnib

Study Phase: Phase 3

Multicenter, Open-label, Efficacy, Safety, Tolerability, and Pharmacokinetic Study of Subcutaneous Ixekizumab With Adalimumab Reference Arm, in Children With Juvenile Idiopathic Arthritis Subtypes of Enthesitis-related Arthritis (Including Juvenile-Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

Enrollment Status: Active_not_recruiting

Publish Date: August 12, 2026

Intervention Type: Drug

Study Drugs: Ixekizumab, Adalimumab

Study Phase: Phase 3

Open-Label, Randomized Study With a Tocilizumab Reference Arm to Evaluate Safety, Efficacy and Pharmacokinetics of Baricitinib in Children From 1 to Less Than 18 Years of Age With Systemic Juvenile Idiopathic Arthritis.

Enrollment Status: Active_not_recruiting

Publish Date: August 11, 2026

Intervention Type: Drug

Study Drug: Baricitinib

Study Phase: Phase 3

An Open-label, Active-Controlled, Safety, and Efficacy Study of Oral Baricitinib in Patients From 2 Years to Less Than 18 Years Old With Active Juvenile Idiopathic Arthritis-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis

Enrollment Status: Active_not_recruiting

Publish Date: April 24, 2026

Intervention Type: Drug

Study Drugs: Baricitinib, Adalimumab

Study Phase: Phase 3

Multicenter, Diagnostic and Prospective Study to Differentiate Child Septic and Inflammatory Arthritis by Comparative Analysis

Enrollment Status: Terminated

Publish Date: April 24, 2026

A Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis (JIA)

Enrollment Status: Completed

Publish Date: October 07, 2022

Intervention Type: Drug

Study Drug: Baricitnib

Study Phase: Phase 3

Human Papilloma Virus Vaccination and Chronic Inflammatory Rheumatic Disease. A Cross-sectional Study of Vaccinal Coverage, Barriers and Motivations.

Enrollment Status: Completed

Publish Date: December 10, 2021

Intervention Type: Other

View 6 Less Clinical Trials

290 Total Publications

HSCT in SAVI: evidence for a curative hematopoietic approach and perspectives for gene therapy.

Journal: Molecular therapy. Advances

Published: July 09, 2026

View All 290 Publications

Frequently Asked Questions about Alexandre Belot

Is Alexandre Belot a top-rated expert for Multisystem Inflammatory Syndrome in Children (MIS-C)?

MediFind is an objective health platform that identifies experts based on real-world data. Alexandre Belot is classified as an Elite expert for Multisystem Inflammatory Syndrome in Children (MIS-C), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Alexandre Belot participate in research or clinical trials?

Yes. Alexandre Belot has published 290 articles and abstracts on conditions like Multisystem Inflammatory Syndrome in Children (MIS-C). You can view a list of Alexandre Belot's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Belot's expertise for a condition

ConditionClose